Release date: 2007-05-14
US research confirms that drug-coated cardiac stents are safe and effective
A recent clinical survey in the United States has shown that drug-coated cardiac stents are safe and effective, and patients with such stents have a lower probability of developing thrombosis.
Drug-coated cardiac stents have been considered a revolution in cardiac interventional therapy, but in recent years their safety has become a topic of debate in the medical community. In September 2006, the results of a study published by experts from Belgium and other countries at the World Heart Congress in Spain showed that patients with drug-coated cardiac stents had a higher risk of thrombosis than patients with ordinary bare metal stents. The results of one study have not been widely recognized.
Researchers at Columbia University conducted a follow-up survey of two major drug-coated cardiac stent products in the North American market. The two-year study included nearly 1,300 patients with drug-coated cardiac stents. Martin Leon, an expert at Columbia University School of Medicine who was in charge of the study, unveiled the results of a recent study at a meeting of the American College of Cardiology, recently concluded: a major cardiac adverse event caused by a drug-coated cardiac stent called Endeavor The rate was 9.3%, while the rate of major cardiac adverse events caused by another drug-coated cardiac stent called Cypher was 11.6%. Both stent products are considered safe and effective according to medical professional standards. In addition, in clinical trials, none of the patients who received the Endeavor drug-coated cardiac stent developed advanced stent thrombosis. Late stent thrombosis is usually formed by blood clots 30 days after the stent is installed, which may lead to a heart attack.
However, industry insiders pointed out that the controversy over the safety of drug-coated cardiac stents is still not over. One of the world's largest drug-coated cardiac stent comparison surveys is being conducted in Europe, and the products under investigation are still the largest share of Endeavor and the market. Cypher these two products.
â€”â€” Information from: China Quality News
Bulk of varicella vaccine,semi-Finished Products.It has good safety with low ratio in adverse reaction. And it has been exported to Bangladesh.
In 2008, BCHT successfully launched its product Varicella Vaccine, Live in China. In the following years, BCHT continuously committed to improving the product and led in 2010 removal of gelatin from adjuvant and extended the vaccine shelf-life up to 36 months which is the longest one in the world in 2011. And it has the following qualities.
Biotechnology Bioproducts Preventive,Final Bulk Medicine Preventive,Final Bulk Pharmaceutical Preventive,Vaccine Biological Products Preventive
Changchun BCHT Biotechnology Co. , https://www.ccbcht.com